Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “HER2-low Cancer”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Not applicableUnknownNCT05834699
What this trial is testing

HER2 Expression of CTC to Predict Response in HER2-low Advanced Breast Cancer Patients Treated With ADC

Who this might be right for
Breast Cancer
Beijing 302 Hospital 50
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07618923
What this trial is testing

Neoadjuvant Dalpiciclib + AI → SHR-A1811 for HR+/HER2-Low Breast Cancer

Who this might be right for
Breast CancerHR Positive/HER2 Low Breast Cancer
Tang-Du Hospital 20
Testing effectiveness (Phase 2)Looking for participantsNCT05150691
What this trial is testing

A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors

Who this might be right for
HER2-positive Advanced Solid Tumor
DualityBio Inc. 796
Large-scale testing (Phase 3)Looking for participantsNCT06492616
What this trial is testing

Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence

Who this might be right for
Breast Cancer
Stemline Therapeutics, Inc. 4,220
Not applicableStudy completedNCT05217381
What this trial is testing

Real-World Data of Clinicopathological Characteristics and Management of Breast Cancer Patients According to HER2 Status

Who this might be right for
Early Breast CancerMetastatic Breast CancerLocally Advanced Breast Cancer
MedSIR 18,533
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06975462
What this trial is testing

A Phase II Study of SHR-A1811 Combined With Radiotherapy in HER2-positive and HER2-low Breast Cancer Brain Metastases

Who this might be right for
Breast Cancer Metastatic
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology 30
Large-scale testing (Phase 3)Study completedNCT01275677
What this trial is testing

Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer

Who this might be right for
HER2/Neu PositiveProgesterone Receptor PositiveRecurrent Breast Carcinoma+6 more
National Cancer Institute (NCI) 3,270
Testing effectiveness (Phase 2)Looking for participantsNCT07661927
What this trial is testing

Skipping Hormone Therapy in Low-Risk Early Breast Cancer

Who this might be right for
Breast Cancer (Early Breast Cancer)
UNICANCER 700
Testing effectiveness (Phase 2)UnknownNCT05749575
What this trial is testing

Chidamide Plus PD-1 Plus Paclitaxel of Neoadjuvant Treatment in Low HR Expression,HER2-negative Early Breast Cancer.

Who this might be right for
Breast Cancer
Sun Yat-sen University 28
Large-scale testing (Phase 3)Looking for participantsNCT05904964
What this trial is testing

Disitamab Vedotin (RC48) in Hormone Receptor Positive, HER2-low Metastatic Breast Cancer (the Rosy Trial)

Who this might be right for
HR Positive/HER2 Low Expression Metastatic Breast Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University 288
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06592625
What this trial is testing

Neoadjuvant SHR-A1811 Plus Adebrelimab in HR Negative/Low & HER2 Low Breast Cancer Patients

Who this might be right for
Untreated Early-stage or Locally Advanced Breast Cancer
Suzhou Suncadia Biopharmaceuticals Co., Ltd. 60
Testing effectiveness (Phase 2)Active Not RecruitingNCT05824325
What this trial is testing

Different Targeted Antibody-drug Conjugates For HER2 Ultra-low or No Expression Advanced Breast Cancer（GALAXY）

Who this might be right for
Breast Cancer
Fudan University 56
Testing effectiveness (Phase 2)UnknownNCT05018676
What this trial is testing

ARX788 in Breast Cancer With Low Expression of HER2

Who this might be right for
Breast Cancer With Low Expression of HER2
Fudan University 54
Not applicableStudy completedNCT06363812
What this trial is testing

Probability of OncotypeDx to Reallocate As Low or High Risk of Recurrence Breast Cancer Patients with Uncertain Biology

Who this might be right for
Breast Cancer
Fondazione Sandro Pitigliani 258
Not applicableLooking for participantsNCT06830382
What this trial is testing

HER2-PET as a Precision Imaging Tool for Treatment With HER2-ADC in HER2-expressing mBC

Who this might be right for
Breast Cancer Stage IVHER2-low Breast CancerMolecular Imaging
Renske Altena 70
Early research (Phase 1)Looking for participantsNCT05872295
What this trial is testing

IKS014 in Advanced Solid Tumors That Express HER2

Who this might be right for
Breast CancerGastric CancerGastroesophageal-junction Cancer
Iksuda Therapeutics Ltd. 165
Testing effectiveness (Phase 2)Study completedNCT00006228
What this trial is testing

Trastuzumab and Interleukin-2 in Treating Patients With Metastatic Breast Cancer

Who this might be right for
HER2-positive Breast CancerMale Breast CancerRecurrent Breast Cancer+1 more
National Cancer Institute (NCI) 37
Testing effectiveness (Phase 2)Study completedNCT00900627
What this trial is testing

Phase I/II AZD8931/Paclitaxel in Treatment of Advanced Solid Tumours (Phase I) and Advanced Breast Cancer (Phase II)

Who this might be right for
NeoplasmsBreast NeoplasmsBreast Cancer
AstraZeneca 330
Testing effectiveness (Phase 2)Looking for participantsNCT04553770
What this trial is testing

Trastuzumab Deruxtecan Alone or in Combination With Anastrozole for the Treatment of Early Stage HER2 Low, Hormone Receptor Positive Breast Cancer

Who this might be right for
Early-stage Breast CancerHormone Receptor Positive Breast CarcinomaInvasive Breast Cancer+4 more
Jonsson Comprehensive Cancer Center 88
Testing effectiveness (Phase 2)Looking for participantsNCT06263543
What this trial is testing

Sequencing Antibody Drug Conjugates in ER+/HER2 LOW/ULTRA LOW MBC

Who this might be right for
Breast CancerMetastatic Breast CancerAdvanced Breast Cancer+2 more
Reshma L. Mahtani, D.O. 75
Next Page